Beta Bionics resumed with a Buy at Stifel

Stifel analyst Jonathan Block resumed coverage of Beta Bionics (BBNX) with a Buy rating and $26 price target The company’s string of “beats and raises” will continue in the near-term amid solid iLet adoption, the analyst tells investors in a research note. Stifel’s survey work suggests the type 2 insulin-intensive opportunity “has legs” for pump providers and that the patch is the preferred form factor.